tiprankstipranks
Analyst Profile
Followed by 879 other investors
.
Cory Kasimov

Cory Kasimov

J.P. Morgan
Wall Street Analyst
Ranked #189 out of 7,991 Analysts on TipRanks (#250 out of 21,404 overall experts)

Success Rate

56%
225 out of 405 Profitable Transactions

Average Return

17.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Cory Kasimov's ratings since 2010 and opened each position for the duration of 1 Year:
55.56% of your transactions would have been profitable with an average return of 17.6%

Stock Rating Distribution

1KRatings
61.36% Buy
34.62% Hold
4.02% Sell
Distribution of Cory Kasimov's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Moderna
(MRNA)
Rating Type:Buy
Dates:Aug 07, 2019 - Jul 20, 2020
Gain:543.40%
The most profitable rating made by Cory Kasimov

Cory Kasimov's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Amylin Pharmaceuticals
Buy
Upgraded
0.00%
1
Arena Pharma
Buy
Upgraded
0.00%
1
ImmunoGen
Hold
Reiterated
0.00%
2
Onyx Pharma
Buy
Reiterated
0.00%
1
Rigel
Hold
Downgraded
0.00%
1
Orexigen
Buy
Reiterated
0.00%
4
Vivus
Hold
Assigned
0.00%
5
Infinity Pharma
Buy
Assigned
$20.00
(1841.75% Upside)
0.00%
2
BioCryst
Buy
Assigned
$18.00
(21.95% Upside)
0.00%
2
JPMorgan Chase & Co.
Hold
Reiterated
0.00%
1
List of latest recommendations made by Cory Kasimov. Click to expand and see Cory Kasimov's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More